Re Directorate

Vectura Group plc

Re Directorate

Chippenham, UK - 8 July: Vectura Group plc (LSE: VEC) ("Vectura"), an industry-leading inhaled airways disease focused business, confirms that as previously announced and as part of the now completed merger agreement with Skyepharma PLC, John Brown will step down from his role as a Non-Executive Director with effect from 10 July 2016. Susan Foden will take over the role of Senior Non-Executive Director with immediate effect.

Bruno Angelici, Chairman, commented:

"On behalf of the Company, I wish to extend my warmest thanks for John Brown's significant contribution to the Board over the past 12 years. John's expert input and counsel has always been well considered and greatly appreciated by his colleagues on the Board, and they wish him well for the future."

The information required to be made available under section 430(2B) of the Companies Act 2006 in relation to John Brown will be made available in the Investors section of the Company's website www.vectura.com at the time of John Brown's departure.

- Ends -

Enquiries

About Vectura

Vectura, a FTSE250 company listed on the London Stock Exchange (LSE: VEC), is an industry-leading inhaled airways disease focused business with proprietary formulation and devices across DPI, pMDI and smart nebulisation platforms. With our extensive range of technologies, capabilities and collaborations, we believe we can become a leader in the development of inhalation products, increasing our ability to help patients suffering from respiratory diseases. In June 2016 Vectura completed a merger with Skyepharma PLC.

Vectura has seven inhaled, four non-inhaled and ten oral products marketed by partners with growing global royalty streams, and a portfolio of drugs in clinical development, a number of which have licence agreements with several global pharmaceutical and biotechnology companies including Hikma, Novartis, Sandoz, Mundipharma, Kyorin, Baxter, GSK, UCB, Ablynx, Grifols, Chiesi, Almirall, Janssen, and Tianjin KingYork.

For further information, please visit Vectura's website at www.vectura.com.

.